2009/01/30 by Mary M. Moran, Javier Guzmán, A. L. Ropars +5 · 247 citations
Immunology and Microbiology · Medicine · #Business #Developing country #Disease #Disease burden #Economic growth #Economics #Environmental health #Global Health and Surgery #Global Maternal and Child Health #Global health #Health care #Investment (military) #Malaria #Medicine #Millennium Development Goals #Neglected tropical diseases #Parasites and Host Interactions #Political science #Population #Tuberculosis
paper · pdf · doi:10.1371/journal.pmed.1000030
published in PLoS Medicine 6(2), e1000030 (Public Library of Science)
openalex publication_date 2009/01/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
he need for new pharmaceutical tools to prevent and treat neglected diseases is widely accepted The creation of a vaccine for HIV/AIDS, more effective diagnostics for tuberculosis (TB), and better treatments for leishmaniasis and sleeping sickness would greatly improve health in the developing world in line with the United Nations Millennium Development Goals. However, funders wishing to invest in this vitally important area currently face an information gap.